#125201
Re: Farmas USA
TEVA
Resultados en una hora.
Resultados en una hora.
Pharmaceutical EPS in-line, misses on revenue
* TEVA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS
* Q3 NON-GAAP EARNINGS PER SHARE $0.58
* Q3 GAAP LOSS PER SHARE $3.97
* Q3 REVENUE $4.0 BILLION
* FULL YEAR 2020 BUSINESS OUTLOOK REVISED
* SEES FY NET REVENUES OF $16.5-$16.8 BILLION
* SEES FY EPS OF $2.40 - $2.55
* TEVA PHARMACEUTICAL - GENERIC PRODUCTS REVENUES IN NORTH
AMERICA
SEGMENT (INCLUDING BIOSIMILARS) IN Q3 OF 2020 WERE $928 MILLION,
AN INCREASE OF 2%
* TEVA PHARMACEUTICAL INDUSTRIES - COPAXONE REVENUE IN NORTH
AMERICA SEGMENT IN Q3 OF 2020 DECREASED BY 13% TO $236 MILLION,
COMPARED TO THIRD QUARTER OF 2019
* AS OF SEPTEMBER 30, 2020, OUR DEBT WAS $25,621 MILLION,
COMPARED
TO $26,266 MILLION AS OF JUNE 30, 2020ETTev
Solo se que no se nada.
Solo se que no se nada.
Salva Marqués